Vendor, Bothell, WA
Cocrystal Pharma, Inc.
UEI UY8UDESGRJ17, CAGE 7SGF5
1 award and $498,199 obligated between September 29, 2025 and September 29, 2025, 100% under full and open competition, against 4.0 offers on average where reported. 12 of the awards trace back to a SAM.gov solicitation on this site.
Industries
NAICS on the awards, by dollars.
| Research and Development in Biotechnology (except Nanobiotechnology)NAICS 541714 | $498,199 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition After Exclusion of Sources | 1 |
| Small Business Set Aside - Total | 1 |
| Definitive Contract | 1 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75N93025C00038Definitive Contract, September 29, 2025, Full and Open Competition After Exclusion of Sources, 4 offersSolicitation | National Institutes of Health NiaidNational Institutes of Health | Development of Pan-Influenza Inhibitors Targeting the PA Endonuclease from the Viral Replication ComplexNAICS 541714, PSC AN12 | $498,199 |
- Places of performance
- Washington
- Product and service codes
- AN12 Health R&D Services; Health Care Services; Applied Research
- Transactions
- 1 across 1 awards